Fund Evaluator:
VanEck Pharmaceutical ETF (PPH)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$55.840
NAV (as of Oct 07)
$0.00
Minimum Initial
0.36% B
Expense Ratio
$925 Mil
Assets
Open
Status
na
12b-1 Fee
1.97%
TTM Yield
0.00%
Max Load
30%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
1.4% B
1-Mo Return
9.0% D
3-Mo Return
8.5% C
YTD Return
35.8% C
1-Yr Return
13.4% B
3-Yr Return
10.2% A
5-Yr Return
0.69 A
Category Risk Index
1.12
Total Risk Index
Fund Details
Fund Family
VanEck
Inception Date
12/20/2011
Share Class Type
Equity Investment Style
Large-Cap
Value
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
MSCI ACWI NR USD: 100%
Additional Fund Details
VanEck Pharmaceutical ETF Overview
PPH Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| PPH Return (NAV) | 1.4% | 9.0% | 35.8% | 13.4% | 10.2% | 8.0% |
| PPH Grade | B | D | C | B | A | D |
| +/- Category | 1.8% | -1.7% | 2.0% | 2.7% | 5.3% | -1.3% |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| PPH Tax Cost Ratio | na | na | 0.9% | 0.8% | 0.8% | 0.8% |
PPH Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| PPH Return (NAV) | 8.5% | 21.9% | 8.1% | 6.9% | 2.7% | 17.8% | 5.4% | 19.0% | -5.5% | 15.4% | -17.8% |
| PPH Grade | C | C | A | A | A | B | F | F | D | F | D |
| +/- Category | 1.4% | 1.3% | 5.6% | 1.4% | 12.1% | 9.1% | -19.1% | -9.4% | -5.9% | -8.0% | -6.9% |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 13.8% |
| Total Risk Index: | 1.12 - Average |
| Category Risk Index: | 0.69 - Low |
| Category Risk Grade: | A (7% Rank) |
| Beta: | 0.40 |
| R-Squared: | 14% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Large-Cap Value |
| Bond Investment Style: | na |
| Yield: | 2.0% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | |
| Total Assets: | $925 Mil |
| Fund Total Assets: | $ 926 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 30% |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 14.6 years | |||
| Average Tenure: 8.6 years | |||
| Managers (Year): Liao Peter (2011), Driscoll Griffin (2024) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 26 |
| % in Top 10 Holdings: | 72.4% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 37.9% |
Portfolio Allocation |
|
| Domestic Stock: | 62.1% |
| Foreign Stock: | 37.9% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.0% |
Purchase Information
| Fund Family: | VanEck |
| Phone Number: | 800-826-2333 |
| Website: | www.marketvectorsetfs.com |
| Status: | Open |
| Inception Date: | December 20, 2011 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.36% ( Rating : Below Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | VanEck Pharmaceutical ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.